Embed Size (px)
Citation preview
ACCELERATING THE SUSTAINABLE CONTROLAND ELIMINATION OF NEGLECTEDTROPICAL DISEASESAn introdu�ion
WHAT IS ASCEND?
Accelerating Su�ainable Control and Elimination of NTDs (ASCEND) is a £200 million inve�ment from the UK government’s Department for International Development, to advance the impa� and su�ainability of national programmes tackling negle�ed tropical diseases (NTDs).
Implemented between September 2019 to March 2022, ASCEND comprises of two lots - one focusing on South Asia, Ea� and Southern Africa (lot 1) and the other on We� and Central Africa (lot 2).ASCEND lot 1 is implemented by a consortium of technical partners lead by Crown Agents, including Abt Associates, Oriole Global Health and the Royal Tropical In�itute. Central to ASCEND 1’s approach is close collaboration with National Governments and other implementing partners, in order to enhance national approaches to NTD control and elimination, resulting in more integrated, co�-e�e�iveand su�ainable programmes.
WHO ARE THE CONSORTIUM PARTNERS?
RESPONSIBLE FOR
Not-for-profit business supporting governments to accelerate self-su�ciency and pro�erity
•Programme management and delivery•Quality assurance•Fund management and value for money •Risk management •Supply chain management and procurement •Stakeholder management
Providing evidence-based solutions to support public health policy formulation and programme design, and co�-e�e�ive evaluations of control options
• Epidemiology and NTD support • Technical expertise in mapping and mass drug admini�ration (MDA)•Impa� assessment to validate and verify elimination•Mathematical modelling
ORIOLEG L O B A L H E A L T H
Global leader in management of health sy�ems
• Health sy�em �rengthening • Health financing • Political economic analysis and support• Advocacy, transition and su�ainability planning
Independent not-for-profit organisation providing technical assi�ance and evaluations in
health programmes globally
• Monitoring, evaluation and learning (MEL) • Behaviour Change Communication (BCC)• Water Sanitation and Hygiene (WASH)
We combine technical and operational expertise in NTDs, WASH, BCC and health sy�ems; layered with Crown Agents’ expertise across a package of services including: robu� fund management, performance and risk management; supply chain, procurement, logi�ics and di�ribution; complex health programme management.
WHICH DISEASES ARE WE TARGETING?
ASCEND 1 will target lymphatic filariasis, onchocerciasis, schi�osomiasis, trachoma andvisceral leishmaniasis.
Also known as elephantiasis; is caused by infe�ion by filarial parasites transmi�ed through the bite of infe�ed female mosquitoes. Infe�ion over long periods leads to damage of the lymphatic sy�em, which can manife� as lymphoedema and hydrocele (scrotal swelling).
Lymphaticfilariasis
Also known as river blindness: is an infe�ion transmi�ed through the bite of infe�ed blackflies, causing severe itching and eye lesions from the microfilaria. If untreated, it can lead to visual impairmentand irreversible blindness.
Onchocerciasis
Also known as bilharzia; is an infe�ion caused by parasitic trematode worms transmi�ed when larval forms, released by freshwater snails, penetrate human skin during conta� with infe�ed water. There are two forms: inte�inal and urogenital schi�osomiasis. Infe�ion can result in abdominal pain, diarrhoea, blood in the �ool / urine and severe complications if le� untreated.
Schi�osomiasis
A chlamydial infe�ion transmi�ed through personal conta� via hands, clothes, flies that have been in conta� with infe�ious discharge from the eyes/nose, facilitated through inadequate hygiene. When le� untreated infe�ion can cause irreversible corneal opacities and blindness.
Trachoma
Also known as kala-azar; is an infe�ion, caused by protozoan parasites, transmi�ed through the bite of infe�ed sandflies. It is the mo� severe form of the disease, with a high mortality rate if not treated.
Visceralleishmaniasis
WHERE DO WE WORK?
We are working with 12 countries in ea�ern & southern Africa and Asia and are targeting the five NTDs in each country as appropriate. Sudan • South SudanEthiopia • Uganda • Kenya • Tanzania • ZambiaMalawi • Mozambique • India • Nepal • Bangladesh
WHAT IS OUR APPROACH?
ASCEND lot 1 will work closely with governments to achieve greater integration in the design and delivery of NTD programming. In addition to providing technical assi�ance, aimed at building government capacity to further the coverage and su�ainability of service delivery, ASCEND will engage a�ors in the NTD programme �ace as sele�ed service-providers. Value-for-Money willbe achieved through competitive open procurement.
ASCEND 1 includes core o�ces in London, as well as regional hubs in both Africa (Nairobi)and Asia (Kathmandu). Regional Managers will support highly experienced Country Leads ineach country, working in close partnership with the Mini�ry of Health, other se�ors and NTD �akeholders. To ensure that technical and delivery support maximises impa�, country engagement will be evidence-based, demand-led and targeted to address identified priority gaps. ASCEND 1 also benefits from an expansive pool of technical advisors in the disease andprogramme fun�ions.
A suite of interventions are available, for these diseases, with overarching interventions such as health sy�em �rengthening (HSS), behaviour change communication (BCC) and water sanitation and hygiene (WASH) improvements forming a critical basis. While mass drug admini�ration (MDA) is implemented for lymphatic filariasis, onchocerciasis, schi�osomiasis and trachoma, early case dete�ion and treatment is vital for visceral leishmanisis.Morbidity management and disease prevention (MMDP) is a crucial component of lymphatic filariasis intervention including hydrocele surgeries. The SAFE �rategy (Surgery of the eyelids, Antibiotics to treat community infe�ion, Facial cleanliness and Environmental improvement) summarizes the combination of interventions for trachoma.
HOW WILL WE ENGAGE WITH GOVERNMENTS AND IMPLEMENTING PARTNERS?
Through partnership with Mini�ries of Health, both demand and supply needs of NTD services will be under�ood and agreed. As such, focus of support will include building local capacity - both in government and civil society – to enable su�ainable, scalable re�onses to NTD control and elimination. The ASCEND 1 approach therefore demands working closely with locally based organisations in each country, as well as national and international non-governmental organisations (NGOs) to re�ond to NTD needs.
Condu�ing Country Situation Analyses, with �rong �akeholder involvement, during the inception period will help determine programme priorities in each country. These are likely to include a mix of the following:• Technical assi�ance to improve government supply chains; �regthen government capacity for mapping and modelling disease prevalence; support decentralisation of government fun�ions for NTDs and build community level health workers’ capacity for NTD programming.
• Dire� treatment interventions via government: including interventions such as trachoma surgeries, morbidity management and behaviour change campaigns.
• Procurement of services from the non-government se�or: including funding to NGOs in order to provide treatments via a competitive fund management process and dire� procurement of services via competitive tender. Crown Agents will issue a general procurement notice inviting Expressions of Intere� for ASCEND, followed by detailed reque�s for proposals.
DFID
London O�ce
Regional Hub
Country Lead
MoH
Technical Resource Pool
Technical Working Group NTD Team WASH Group
Technical Partners Delivery Partners
Advocacy and transition & su�ainability planning • MappingMDA • Morbidity management • Diagnosis and referral capacity
Surveillance • Behaviour change communicationSupply chain management
Impa� Assessment and Validation of elimination • HSS • WASH
COUNTRY UNIT
GLOBAL
REGIONAL
COUNTRY
Consortium
Government
Partner
Consortium andDown�ream Partner
Global Partners and WHO
Local Partners andWHO Country O�ce
WHAT IS OUR AIM?
The key results the consortium aims to deliver: • Scale-up programme coverage and MDA treatments delivered in target countries• Provide surgeries to prevent cases of blindness due to trachoma • Reduce morbidity and disability of people with lymphatic filariasis• Early diagnosis and treatment of visceral leishmaniasis
WHO TO CONTACT
Blue Fin Building110 Southwark StreetLondon SE1 0SU England
T +44 (0)20 3940 4000 [email protected]
Crown Agents LimitedRegi�ered in England and Wales No. 3259922VAT Reg. No. GB 340 6798 41
Team Leader
Deputy Team Leader
Programme Manager
Programme Dire�or
Africa Regional Managers
Asia Regional Manager
Ethiopia Country Lead
Kenya Country Lead
South Sudan Country Lead
Zambia Country Lead
Malawi Country Lead
Mozambique Country Lead
Sudan Country Lead
Tanzania Country Lead
Uganda Country Lead
Bangladesh Country Lead
India Country Lead
Nepal Country Lead
Kate Wilson Hargreaves (London)
Iain Gardiner (London)
Shodigul Alimshoeva (London)
Stefan Lawson (London and Juba)
Elodie Yard (Nairobi)
Edridah Muheki (Nairobi)
Sharad Barkataki (Kathmandu and Dhaka)
Fentahun Tadesse (Addis Ababa)
Duncan Ochol Ochieng (Nairobi)
Ajadit Kuol (Juba)
Roman Mukendi (Lusaka)
Timothy Kachule (Lilongwe)
Gertrudes Machatine (Maputo)
Abdul Raouf Qawas (Amman)
Deogracias Ngoma (Dar Es Salaam)
Narcis Kabatereine (Kampala)
Be-Nazir Ahmed (Dhaka)
Ekta Saroha (Delhi)
Na�u Sharma (Kathmandu)
All
All
All
All
EthiopiaKenyaSouth SudanZambia
MalawiMozambiqueSudanTanzaniaUganda
BangladeshIndiaNepal
Ethiopia
Kenya
South Sudan
Zambia
Malawi
Mozambique
Sudan
Tanzania
Uganda
Bangladesh
India
Nepal
[email protected] +44 7951695737
ROLE NAME AND LOCATION COUNTRIES CONTACT
ORIOLEG L O B A L H E A L T H
